Senti Biosciences replaced KPMG as its independent auditor, effective Nov. 17, and appointed KNAV CPA to audit the company’s 2026 financial statements. The change comes against a backdrop of prior audit reports that raised substantial doubt about Senti’s ability to continue as a going concern, though the company reported no unresolved accounting or auditing disagreements with KPMG.
- Auditor transition: Senti dismissed KPMG on Nov. 17. Its audit committee approved KNAV’s appointment on Nov. 20 for the fiscal year ending Dec. 31, 2026. The company did not state a reason for the change.
- KPMG’s prior reports: KPMG’s reports on Senti’s 2024 and 2025 financial statements were not qualified, but each included an explanatory paragraph citing substantial doubt about the company’s ability to continue as a going concern. The concerns cited recurring losses, negative cash flow from operations and an accumulated deficit.
- No reported disputes: Senti said there were no disagreements with KPMG over accounting, financial-statement disclosures or audit procedures during 2024 and 2025 or the period leading up to the dismissal.
- Prior control weakness: The only reportable issue cited was a material weakness in internal controls that existed at the end of 2024. It stemmed from insufficient finance and accounting resources, which affected controls over unusual, non-routine or complex transactions. Senti said management concluded the weakness was remediated during 2025.
- KNAV’s prior involvement: Senti said neither it nor anyone acting on its behalf consulted KNAV about accounting or audit matters before the firm’s appointment.
The auditor change does not, on its own, indicate a dispute with KPMG: Senti reported none. The going-concern language in KPMG’s earlier reports remains an important part of the company’s financial context; the filing does not say that the auditor transition changes that assessment.
